Matthew Winkler - Jun 1, 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Director
Signature
/s/ Matthew Winkler, by Brian McKelligon, as Attorney-in-Fact
Stock symbol
AKYA
Transactions as of
Jun 1, 2022
Transactions value $
$0
Form type
4
Date filed
6/3/2022, 04:07 PM
Previous filing
May 25, 2021
Next filing
Jun 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKYA Common Stock 781K Jun 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Stock Option (Right to Buy Award $0 +30.5K $0.00 30.5K Jun 1, 2022 Common Stock 30.5K $11.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2023, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.